# Relative Bio-availability Study of Dolutegravir and Lamivudine Fixed Dose Combinations

> **NCT02738931** · PHASE1 · COMPLETED · sponsor: **ViiV Healthcare** · enrollment: 30 (actual)

## Conditions studied

- Infection, Human Immunodeficiency Virus

## Interventions

- **DRUG:** Dolutegravir 50 mg tablet
- **DRUG:** Lamivudine 300 mg tablet
- **DRUG:** Dolutegravir/Lamivudine 50 mg/300 mg Tablet (Product Code AA)
- **DRUG:** Dolutegravir/Lamivudine 50 mg/300 mg Tablet (Product Code AB)

## Key facts

- **NCT ID:** NCT02738931
- **Lead sponsor:** ViiV Healthcare
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-05
- **Primary completion:** 2016-06
- **Final completion:** 2016-06
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2017-01-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02738931

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02738931, "Relative Bio-availability Study of Dolutegravir and Lamivudine Fixed Dose Combinations". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02738931. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*